Plasma homocysteine levels and risk of congestive heart failure or cardiomyopathy: A Mendelian randomization study

BACKGROUND: Although observational studies have demonstrated associations between elevated plasma homocysteine levels and the risk of cardiovascular diseases, controversy remains. OBJECTIVE: This study investigated the causal association of plasma homocysteine levels with congestive heart failure an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinyi, Chen, Zhuo, Tian, Wende, Zhang, Jie, Li, Qiuyi, Ju, Jianqing, Xu, Hao, Chen, Keji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908956/
https://www.ncbi.nlm.nih.gov/pubmed/36776266
http://dx.doi.org/10.3389/fcvm.2023.1030257
Descripción
Sumario:BACKGROUND: Although observational studies have demonstrated associations between elevated plasma homocysteine levels and the risk of cardiovascular diseases, controversy remains. OBJECTIVE: This study investigated the causal association of plasma homocysteine levels with congestive heart failure and cardiomyopathy risk. METHODS: We performed a two-sample Mendelian randomization (MR) study of congestive heart failure (n = 218,792), cardiomyopathy (n = 159,811), and non-ischemic cardiomyopathy (n = 187,152). Genetic summary data on the association of single-nucleotide polymorphisms with homocysteine were extracted from the most extensive genome-wide association study of 44,147 individuals. MR analyses, including the random-effect inverse variance-weighted (IVW) meta-analysis, weighted median, simple median, maximum likelihood, penalized weighted median, MR-PRESSO, and MR-Egger regression, were used to estimate the associations between the selected single-nucleotide polymorphisms and congestive heart failure or cardiomyopathy. RESULTS: The MR analyses revealed no causal role of higher genetically predicted plasma homocysteine levels with congestive heart failure risk (random-effect IVW, odds ratio [OR] per standard deviation (SD) increase in homocysteine levels = 1.753, 95% confidence interval [CI] = 0.674–4.562, P = 0.250), cardiomyopathy (random-effect IVW, OR per SD increase in homocysteine levels = 0.805, 95% CI = 0.583 to 1.020, P = 0.189), or non-ischemic cardiomyopathy (random-effect IVW, OR per SD increase in homocysteine levels = 1.064, 95% CI = 0.927–1.222, P = 0.379). The results were consistent with other analytical methods and sensitivity analyses. CONCLUSION: Genetically predicted homocysteine level was not associated with congestive heart failure or cardiomyopathy risk. It is unlikely that homocysteine-lowering therapy decreases the incidence or improves the outcomes of congestive heart failure and cardiomyopathy.

Ejemplares similares